0 153

Cited 12 times in

Long-term effectiveness of flexibly dosed paliperidone extended-release: comparison among patients with schizophrenia switching from risperidone and other antipsychotic agents

 Eun Young Kim  ;  Sung Man Chang  ;  Joo Cheol Shim  ;  Eun Jeong Joo  ;  Jae Jin Kim  ;  Yong Sik Kim  ;  Yong Min Ahn 
 CURRENT MEDICAL RESEARCH AND OPINION, Vol.29(10) : 1231-1240, 2013 
Journal Title
Issue Date
Adolescent ; Adult ; Aged ; Antipsychotic Agents/administration & dosage* ; Female ; Humans ; Isoxazoles/administration & dosage* ; Male ; Middle Aged ; Paliperidone Palmitate ; Prospective Studies ; Pyrimidines/administration & dosage* ; Risperidone/administration & dosage ; Schizophrenia/drug therapy* ; Schizophrenia/pathology ; Schizophrenia/physiopathology ; Severity of Illness Index
OBJECTIVE: The current study compared the long-term effectiveness, safety, and tolerability of paliperidone extended-release (ER) among patients with schizophrenia who had switched from risperidone (risperidone group) or other antipsychotic medications (non-risperidone group) due to lack of efficacy, intolerability, or non-adherence. RESEARCH DESIGN AND METHODS: This open-label, prospective, multicenter, 48 week study utilized the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression-Severity scale (CGI-S), the Personal and Social Performance scale (PSP), and the Subjective Well-being under Neuroleptics scale (SWN) to assess patients with schizophrenia. Additionally, extrapyramidal symptoms (EPS) and subjective side effects were evaluated with validated scales. CLINICAL TRIAL REGISTRATION: Clinicaltrials.gov identifier: NCT00864045. RESULTS: The completion rate for this study was 51.6% (95/184), and 169 patients finished with ≥1 post-baseline assessment (81 patients in the risperidone group, 88 in the non-risperidone group). The mean (SD) PANSS total score decreased significantly from 78.3 (18.8) to 65.5 (19.7) in the risperidone group and from 79.1 (19.8) to 65.4 (20.8) in the other group (all p < 0.001). Similar to PANSS, the severity rating for overall scores of the CGI-S and the PSP scores improved significantly from baseline (all p < 0.001). The magnitude of improvement in all effectiveness measures at 48 weeks did not differ between the two groups. EPS and subjective side effects improved significantly for all patients. Akathisia (18.5%) and increased weight (14.1%) were the main adverse events. Elevated prolactin levels were identified in female subjects in the non-risperidone group. CONCLUSIONS: Switching from previously unsuccessful antipsychotic treatments to paliperidone ER can be a useful option to achieve long-term improvement in symptoms and functioning for patients with schizophrenia. The clinical effectiveness appeared to be similar in patients who previously received risperidone and those treated with other antipsychotic medications. The open-label design and lack of a placebo group were limitations.
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
Yonsei Authors
Kim, Jae Jin(김재진) ORCID logo https://orcid.org/0000-0002-1395-4562
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.